Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms?

Expert Opinion on Investigational Drugs

Volumn 22, Issue 8, 2013, Pages 941-943

  Corbett, Anne ^a   Ballard, Clive ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Pharmacological; Repositioning

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DONEPEZIL; EXENDIN 4; GALANTAMINE; LIRAGLUTIDE; MEMANTINE; MINOCYCLINE; NIMODIPINE; RETINOID; RIVASTIGMINE;

ACNE; ALZHEIMER DISEASE; DEMENTIA; DIABETES MELLITUS; DRUG REPOSITIONING; HEADACHE; HUMAN; HYPERTENSION; LIVER FUNCTION; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PALLIATIVE THERAPY; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN EXFOLIATION;

ALZHEIMER DISEASE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTI-BACTERIAL AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG REPOSITIONING; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84880243950     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.815723     Document Type: Review

References (16)

1. Wimo A, Jonsson L, Bond J, et al. Alzheimer disease international. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013;9(1):1-11.e3
2. Ballard C, Corbett A, Sharp S. Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease. Expert Rev Neurother 2011;11(3):327-9
3. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 2001;10(9):698-712
4. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: Clinical trials and drug development. Lancet Neurol 2010;9(7):702-16
5. Salomone S, Caraci F, Leggio GM, et al. New pharmacological strategies for treatment of Alzheimer's disease: Focus on disease modifying drugs. Br J Clin Pharmacol 2012;73(4):504-17
6. Ashburn T, Thor K. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3(8):673-83
7. Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov 2012;11(11):833-46
8. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer's disease -friend or foe? Trends Neurosci 2009;32(12):619-28
9. Danielyan L, Klein R, Hanson LR, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 2010;13(2-3):195-201
10. Anekonda TS, Quinn JF, Harris C, et al. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis 2011;41(1):62-70
11. Lo'pez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002(3):CD000147
12. Moloney AM, Griffin RJ, Timmons S, et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010;31(2):224-43
13. McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011;31(17):6587-94
14. The NINDS NET-PD Investigators. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 2008;31(3):141-50
15. Seabrook TJ, Jiang L, Maier M, Lemere CA. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 2006;53(7):776-82
16. Shudo K, Fukasawa H, Nakagomi M, Yamagata N. Towards retinoid therapy for Alzheimer's disease. Curr Alzheimer Res 2009;6(3):302-11